Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/6/2024 | $25.60 | Buy | Berenberg | |
| 3/6/2024 | $133.00 | Equal Weight | Barclays | |
| 1/8/2024 | Equal-Weight → Underweight | Morgan Stanley | ||
| 11/24/2023 | Reduce → Hold | HSBC Securities | ||
| 11/17/2023 | Hold → Buy | Societe Generale | ||
| 8/14/2023 | Buy → Neutral | UBS | ||
| 8/7/2023 | $100.00 → $142.00 | Neutral → Buy | UBS | |
| 8/1/2023 | Neutral | Citigroup |
Strategic Relationship: Agreement expands access to ECMO solutions for hospitals, health systems and patients in the U.S. nationwide.Wide Reach: 4,350+ Premier member hospitals and health systems in the U.S. can leverage pre-negotiated terms and pricing on the Novalung System for ECMO.Commitment to Quality Care: Reinforces company's commitment to supporting healthcare providers in their efforts to deliver high-quality critical care treatments and solutions.BAD HOMBURG, Germany, Nov. 19, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced its heart and lung group has been awarded a nation
DENVER, Nov. 8, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) today announced that its chief financial officer, Joel Ackerman, and its group vice president of investor relations, Nic Eliason, will participate in a fireside chat with investors at UBS Global Healthcare Conference 2024 on Tuesday, November 12, 2024 at 12:30 pm PST (3:30 pm EST). To view the live webcast, visit the UBS page here and create a free registration. About DaVita Inc. DaVita (NYSE:DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. As a comprehensive kidney care provider, DaVita has been a leader in clinical quality and innovation for more than 20 years.
Organic revenue growth of +2% supported by Care Enablement and Care DeliveryUnderlying U.S. dialysis treatment volume growth turns positiveExceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3Both segments further increased operating income1 and operating income margin1Net financial leverage ratio further improved to 2.8xFY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The C
Organic revenue growth of +2% supported by Care Enablement and Care DeliveryUnderlying U.S. dialysis treatment volume growth turns positiveExceeding full year FME25 savings target, with additional EUR 64 million contribution in Q3Both segments further increased operating income1 and operating income margin1Net financial leverage ratio further improved to 2.8xFY 2024 operating income1 growth outlook with 16-18% tightened toward the upper end of the previous rangeBAD HOMBURG, Germany, Nov. 5, 2024 /PRNewswire/ -- "In the third quarter, we continued the improvement of our financial performance, recording a meaningful progress in the operating income margin towards our 2025 margin targets. The C
DENVER, Oct. 29, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA) announced financial and operating results for the quarter ended September 30, 2024. "We continue to provide quality care for our patients across the continuum of care, while delivering solid third quarter financial performance," said Javier Rodriguez, CEO of DaVita Inc. "And, in light of recent severe storms, I am grateful for the remarkable resilience of our patients and our frontline caregivers." Financial and operating highlights for the quarter ended September 30, 2024: Consolidated revenues were $3.264 billion.Operating income was $535 million.Diluted earnings per share was $2.50 and adjusted diluted earnings per share was $2.
DENVER, Oct. 9, 2024 /PRNewswire/ -- DaVita Inc. (NYSE:DVA), announced today that it will hold its quarterly conference call to discuss third quarter results on Tuesday, October 29, 2024, at 5:00 p.m. Eastern Time. The company plans to release its results after market close the same day. This call is also being webcast and can be accessed at the DaVita IR web page. You can join this call as follows: Tuesday, October 29, 2024Starting at 5:00 p.m. EDTWebcast can be accessed using this link Dial in number: 877-918-6630International dial in: 517-308-9042 When calling in, please provide the operator the password "Earnings" and provide your name and company affiliation. Investors unable to listen
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
4 - DAVITA INC. (0000927066) (Issuer)
SC 13G - Fresenius Medical Care AG (0001333141) (Subject)
SC 13G/A - DAVITA INC. (0000927066) (Subject)
SC 13G/A - Fresenius Medical Care AG (0001333141) (Subject)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
6-K - Fresenius Medical Care AG (0001333141) (Filer)
10-Q - DAVITA INC. (0000927066) (Filer)
Berenberg initiated coverage of Fresenius Medical with a rating of Buy and set a new price target of $25.60
Barclays initiated coverage of DaVita with a rating of Equal Weight and set a new price target of $133.00
Morgan Stanley downgraded Fresenius Medical from Equal-Weight to Underweight
TD Cowen analyst Gary Taylor maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $139 to $150.
DaVita Inc. (NYSE:DVA), a Colorado-based kidney dialysis provider, agreed to pay $34.5 million for allegedly paying kickbacks to a competitor for making referrals to DaVita Rx, a former subsidiary that provided pharmacy services for dialysis patients. DaVita also allegedly paid kickbacks to nephrologists and vascular access physicians to get patient referrals to DaVita's dialysis centers, the U.S. Department of Justice (DOJ) said on Thursday. The DOJ said DaVita violated the False Claims Act’s Anti-Kickback Statute, which prohibits providing any payments that are intended to induce referrals of patients or items or services covered by Medicare, Medicaid and other federally funded progr
- Bloomberg Citing DOJ
DENVER, Oct. 17, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced Jessica (Jess) Hergenreter as its new chief people officer (CPO). In this position, Hergenreter will oversee DaVita's People Services team, leading initiatives to engage and uplift DaVita's more than 70,000 teammates (employees) worldwide. Earlier this year, DaVita was named as a Top Workplace by USA Today and one of America's Most Loved Companies by Newsweek. "Our incredible teammates are the difference makers for the care we provide to patients," said Javier Rodriguez, C
DENVER, Sept. 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that David Maughan will assume the role of chief operating officer. This appointment builds on Maughan's 18-year tenure at DaVita in a range of leadership roles. After a celebrated 11-year tenure as chief operating officer, Mike Staffieri will step into the role of chief operating officer emeritus. Both appointments are effective September 15, 2024. "It's an exciting time for DaVita! Dave's extensive experience in operations leadership coupled with his deep knowledge of DaVita's business positions him well to build upon our incredible foundation of operational excellence and lead our on
Madhu Narasimhan named to leadership role to accelerate technology-based innovations at DaVita DENVER, May 13, 2024 /PRNewswire/ -- DaVita, a leading provider of kidney care services, today announced that Madhu Narasimhan will assume the role of chief information officer (CIO), effective June 3, 2024. In this leadership position, Narasimhan will be responsible for accelerating the implementation of DaVita's industry-leading health technology platforms. She will oversee DaVita's technology innovation strategy, including enterprise priorities like Center Without Walls™ (CWOW®),